NewsNTech
Preliminary data from an early human trial show that an experimental skin cream, RLS-1496, was associated with a 2.1-year decrease in measured epigenetic skin age after four weeks of treatment.
Rubedo Life Sciences, a biotechnology company based in Mountain View, California, released the findings this week, noting that the analysis included 11 paired skin samples from patients with atopic dermatitis and other skin conditions.
The company's chief executive officer, Dr. Frederick Beddingfield, described the results as "significant" early findings that warrant further investigation.
In a statement to Fox News Digital, Beddingfield said the drug is one of the few developed for aging in general and using AI to show positive data in humans across multiple indications.
Keep reading